Press & Media

GoodOnes™ in the news.

GoodOnes™ is the consumer line of Flore Clinical, founded by Craig Rouskey. Coverage spans probiotics for neurodiversity, microbiome science, and precision gut health. Press inquiries: [email protected]

Flore Clinical has been covered by leading trade publications and mainstream media across topics including personalized microbiome mapping, autism spectrum probiotic support, and the emerging field of precision gut health. The GoodOnes™ line — ten system-matched targeted probiotic formulas built on a longitudinal dataset of 23,447 sequenced microbiomes — represents Flore's translation of clinical research into a consumer product line.

GoodOnes™ & Flore Clinical — Recent Coverage

The Food Institute Can Probiotics Improve Autism Symptoms? One Brand Believes So 2024 The Food Institute examined Flore's approach to formulating probiotics specifically for the autism and neurodiversity market, including the gut-vagus signalling rationale behind the Calm One and Gentle One formulas. Globe Newswire Flore Unveils World's First Line of Probiotics for Neurodiversity September 2024 Official announcement of Flore's neurodiverse probiotic line, covering the gut-brain axis research behind the formulas, strain selection rationale, and the Calm One and Gentle One product categories. Nutraceuticals World Flore Launches Probiotic Line Formulated for Neurodiversity September 2024 Nutraceuticals World covered Flore's formal launch of targeted probiotic formulas for neurodiverse individuals, highlighting the Bifidobacterium and Lactobacillus strain pairs selected for gut-vagal signalling support. VitaFoods Insights Flore Launches World's First Line of Probiotics Targeting Neurodiversity September 2024 VitaFoods Insights placed Flore's neurodiversity probiotic line in the broader context of gut-brain axis research, noting the longitudinal microbiome dataset behind the strain selections. Nutrition Insight Flore Unveils World's First Probiotics Portfolio for Neurodiversity September 2024 Nutrition Insight reported on the scientific rationale behind Flore's neurodiverse probiotic portfolio, including the distinction between adult (Calm One) and pediatric (Gentle One) formulations at different doses and prebiotics. Nutraceutical Business Review Flore Debuts First Ever Probiotic Line Catered to Neurodiverse Individuals 2024 Nutraceutical Business Review highlighted Flore's pathways-based approach to formulation, explaining how the gut-vagus axis connects microbiome composition to neurological function and mood regulation. NutraIngredients Flore Clinical Makes Personalized Microbiome Mapping Tech More Accessible to Clinicians June 2024 NutraIngredients profiled Flore Clinical's initiative to bring at-home microbiome sequencing and personalized probiotic formulation to clinicians and their patients at lower cost and with faster turnaround. BioSpace Clinical Study Highlights Improvements to Gut Microbiome and Autism Spectrum Disorder Symptoms 2024 BioSpace covered peer-reviewed clinical research showing measurable improvements in gut microbiome composition and ASD-associated symptom scores following custom probiotic supplementation with Flore formulas. KXAN Austin Flore Clinical Teams Up with Evexia Diagnostics to Reach 20,000 Clinicians 2024 Flore Clinical announced a partnership with Evexia Diagnostics to distribute its personalized microbiome mapping technology through a network of 20,000 practitioner clinicians across the United States. Nutritional Outlook Personalized-Probiotics Brand Flore Now Offering At-Home Stool Analysis Test February 2026 Nutritional Outlook reported on Flore's at-home stool analysis offering, which allows consumers to sequence their gut microbiome and receive a personalized probiotic formula matched to their individual sequencing data.

Founder Coverage — Craig Rouskey

Craig Rouskey is CEO of Flore Inc. and the scientist behind GoodOnes™ targeted probiotic formulas. He holds an MSc in Molecular Biology, Microbiology, Biochemistry & Immunology (Southern Illinois University) and a BSc in Biology (University of St. Francis). Prior to Flore, he led COVID-19 diagnostics at Renegade Bio and animal nutrition data science at Pando. He is a TEDxBellevue speaker on citizen science and precision health. Full biography →

HAPPI Wellness Brand Flore Welcomes Craig Rouskey as New CEO 2023 HAPPI (Household and Personal Products Industry) covered Craig Rouskey's appointment as CEO of Flore Inc., noting his background in molecular biology, genomics, and translational microbiome research. TEDxBellevue Citizen Science — From Institutions to Community TEDx Talk Craig Rouskey's TEDxBellevue talk on bringing citizen science into mainstream health research — how community-driven data collection and precision diagnostics can accelerate breakthroughs that institutions alone cannot reach. San Diego Patch Customized Probiotic Brand Flore Welcomes Craig Rouskey as New CEO 2023 San Diego Patch profiled Craig Rouskey's transition to CEO of Flore, describing his scientific background and vision for using longitudinal microbiome data to build precision probiotic products for consumers and clinicians.

Research & Funding History

Flore Inc. (formerly Sun Genomics) has raised institutional capital from DSM and Series A investors to build its microbiome sequencing and personalized probiotic platform. The clinical-grade infrastructure underlying the GoodOnes™ consumer line was built on this research foundation.

NutraIngredients DSM Partners Sun Genomics Precision Probiotic Brand Flore January 2023 Global nutrition leader DSM partnered with Flore (then Sun Genomics) to advance its precision probiotic formulation platform, lending scientific and commercial infrastructure to the personalized microbiome program. PR Newswire Sun Genomics Secures $8.65 Million Series A Financing 2020 Sun Genomics (now Flore Inc.) closed an $8.65 million Series A round to scale its microbiome sequencing laboratory, expand the at-home test kit program, and invest in the clinical research infrastructure that now underpins GoodOnes™. San Diego Business Journal With $8.7 Million in Series A Funding, Sun Genomics Plans to Scale July 2020 The San Diego Business Journal profiled Sun Genomics' Series A growth plans, including lab expansion, clinician partnerships, and the longitudinal sequencing program that now underlies the 23,447-gut GoodOnes™ dataset.

Press Inquiries

Media contact: [email protected]
For product samples, founder interviews, or clinical data requests, please include your publication and deadline.

Additional resources: About GoodOnes™ · Mechanism Library · Flore Clinical